Gelmon KA - Search Results

1

Preferential dependence of breast cancer cells versus normal cells on integrin-linked kinase for protein kinase B/Akt activation and cell survival.

Troussard AA, McDonald PC, Wederell ED, Mawji NM, Filipenko NR, Gelmon KA, Kucab JE, Dunn SE, Emerman JT, Bally MB, Dedhar S. Troussard AA, et al. Among authors: gelmon ka. Cancer Res. 2006 Jan 1;66(1):393-403. doi: 10.1158/0008-5472.CAN-05-2304. Cancer Res. 2006. PMID: 16397254 Free article.

2

Modulation of doxorubicin resistance in P388/ADR cells by Ro44-5912, a tiapamil derivative.

De Jong G, Gelmon K, Bally M, Goldie J, Mayer L. De Jong G, et al. Anticancer Res. 1995 May-Jun;15(3):911-6. Anticancer Res. 1995. PMID: 7645981

3

Validation of a high-performance liquid chromatographic assay method for quantification of total vincristine sulfate in human plasma following administration of vincristine sulfate liposome injection.

Embree L, Gelmon KA, Tolcher AW, Hudon NJ, Heggie JR, Dedhar C, Webb MS, Bally MB, Mayer LD. Embree L, et al. Among authors: gelmon ka. J Pharm Biomed Anal. 1997 Dec;16(4):675-87. doi: 10.1016/s0731-7085(97)00087-3. J Pharm Biomed Anal. 1997. PMID: 9502163

4

Pharmacokinetic behavior of vincristine sulfate following administration of vincristine sulfate liposome injection.

Embree L, Gelmon K, Tolcher A, Hudon N, Heggie J, Dedhar C, Logan P, Bally MB, Mayer LD. Embree L, et al. Cancer Chemother Pharmacol. 1998;41(5):347-52. doi: 10.1007/s002800050750. Cancer Chemother Pharmacol. 1998. PMID: 9523729 Clinical Trial.

5

Preclinical pharmacology, toxicology and efficacy of sphingomyelin/cholesterol liposomal vincristine for therapeutic treatment of cancer.

Webb MS, Logan P, Kanter PM, St-Onge G, Gelmon K, Harasym T, Mayer LD, Bally MB. Webb MS, et al. Cancer Chemother Pharmacol. 1998;42(6):461-70. doi: 10.1007/s002800050846. Cancer Chemother Pharmacol. 1998. PMID: 9788572

6

Phase I study of liposomal vincristine.

Gelmon KA, Tolcher A, Diab AR, Bally MB, Embree L, Hudon N, Dedhar C, Ayers D, Eisen A, Melosky B, Burge C, Logan P, Mayer LD. Gelmon KA, et al. J Clin Oncol. 1999 Feb;17(2):697-705. doi: 10.1200/JCO.1999.17.2.697. J Clin Oncol. 1999. PMID: 10080616 Clinical Trial.

7

Absence of mutations in the ATM gene in forty-seven cases of sporadic breast cancer.

Bebb DG, Yu Z, Chen J, Telatar M, Gelmon K, Phillips N, Gatti RA, Glickman BW. Bebb DG, et al. Br J Cancer. 1999 Aug;80(12):1979-81. doi: 10.1038/sj.bjc.6690630. Br J Cancer. 1999. PMID: 10471049 Free PMC article.

8

In vitro characterization of the anticancer activity of membrane-active cationic peptides. I. Peptide-mediated cytotoxicity and peptide-enhanced cytotoxic activity of doxorubicin against wild-type and p-glycoprotein over-expressing tumor cell lines.

Johnstone SA, Gelmon K, Mayer LD, Hancock RE, Bally MB. Johnstone SA, et al. Anticancer Drug Des. 2000 Apr;15(2):151-60. Anticancer Drug Des. 2000. PMID: 10901303

9

Combining doxorubicin and liposomal anti-HER-2/NEU antisense oligodeoxynucleotides to treat HER-2/NEU-expressing MDA-MB-435 breast tumor model.

Waterhouse DN, Gelmon KA, Masin D, Bally MB. Waterhouse DN, et al. Among authors: gelmon ka. J Exp Ther Oncol. 2003 Sep-Oct;3(5):261-71. doi: 10.1111/j.1533-869x.2003.01099.x. J Exp Ther Oncol. 2003. PMID: 14696623

10

Pharmacodynamic behavior of liposomal antisense oligonucleotides targeting Her-2/neu and vascular endothelial growth factor in an ascitic MDA435/LCC6 human breast cancer model.

Waterhouse DN, Dragowska WH, Gelmon KA, Mayer LD, Bally MB. Waterhouse DN, et al. Among authors: gelmon ka. Cancer Biol Ther. 2004 Feb;3(2):197-204. Epub 2004 Feb 1. Cancer Biol Ther. 2004. PMID: 14726684

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

236 results

Search Page